Chronic myelogenous leukemia (CML) is coded in ICD-10 as C92.1, “chronic myeloid leukemia, BCR/ABL-positive.” It is caused by an acquired genetic change called the Philadelphia chromosome, and today it is managed mainly with daily oral tablets called tyrosine kinase inhibitors (TKIs). For most people diagnosed in the chronic phase, CML has become a long-term, controllable condition rather than a rapidly fatal one.
This article covers the coding details clinicians and coders need, then explains what causes CML, how it is diagnosed, and how treatment and monitoring work in practice.
What Is Chronic Myelogenous Leukemia?
CML is a cancer of the blood-forming stem cells in the bone marrow. It belongs to the myeloproliferative neoplasms, a family of hematologic disorders in which the marrow overproduces one or more blood cell lines. In CML, the excess cells are granulocytes, a type of white blood cell, at every stage of maturity.
Unlike acute leukemia, CML cells still mature and function reasonably well at first. That is why many patients feel fine and are diagnosed only after a routine blood test shows a very high white count. The marrow itself, whose normal structure is described in our guide to bone marrow composition and function, becomes packed with myeloid cells.
Untreated, CML moves through phases of increasing severity: the chronic phase, an accelerated phase, and a blast phase that behaves like acute leukemia. Effective TKI therapy has made progression much less common.
Chronic Myelogenous Leukemia ICD-10 Codes
In ICD-10, CML sits under C92, “myeloid leukemia.” The US clinical modification (ICD-10-CM) adds a fifth character that records remission status, which matters for accurate documentation and billing.
| Code | Description | When it applies |
|---|---|---|
| C92.1 | Chronic myeloid leukemia, BCR/ABL-positive | Parent category for classic CML |
| C92.10 | CML, BCR/ABL-positive, not having achieved remission | New diagnosis or active disease |
| C92.11 | CML, BCR/ABL-positive, in remission | Documented remission on treatment |
| C92.12 | CML, BCR/ABL-positive, in relapse | Loss of a previously achieved response |
| C92.2 | Atypical chronic myeloid leukemia, BCR/ABL-negative | A different disease; not classic CML |
A common coding pitfall is using C92.2 for ordinary CML. Atypical CML lacks the BCR-ABL1 fusion, behaves differently, and does not respond to TKIs in the same way, so the distinction has real clinical meaning. Coders should also rely on the physician’s documentation of remission rather than inferring it from lab values.
Causes and Risk Factors
CML begins when parts of chromosomes 9 and 22 swap places inside a single marrow stem cell. This translocation, written t(9;22), creates a shortened chromosome 22, the Philadelphia chromosome, and fuses two genes into a new one called BCR-ABL1.
The BCR-ABL1 gene produces a tyrosine kinase that is permanently switched on. It drives relentless cell division and helps the leukemic cells resist normal cell death, so their descendants gradually crowd out healthy blood production.
- Acquired, not inherited: the translocation arises during a person’s life and is not passed to children.
- Radiation exposure: high-dose ionizing radiation is the only well-established environmental risk factor.
- Age: CML can occur at any age but is most often diagnosed in middle-aged and older adults; it is rare in children.
- No lifestyle cause: diet, stress, and ordinary chemical exposures have not been shown to cause CML.
Signs, Symptoms, and Diagnosis
Many patients have no symptoms in the chronic phase. When symptoms do appear, the most common are fatigue, night sweats, weight loss, and a feeling of fullness or discomfort under the left ribs from an enlarged spleen (splenomegaly). In advanced phases, patients may develop bone pain, fever, infections, and bleeding as the leukemia progresses toward bone marrow failure.
Diagnosis combines hematological testing with genetic confirmation:
- Complete blood count and blood film: a high white count with granulocytes at all stages, often with increased basophils and sometimes a raised platelet count.
- Bone marrow aspirate and biopsy: assesses cellularity, blast percentage, and fibrosis, which define the phase.
- Cytogenetics or FISH: detects the Philadelphia chromosome, present in the large majority of cases.
- Quantitative PCR (qPCR): measures BCR-ABL1 transcript levels, the baseline for all future monitoring.
Management: Tyrosine Kinase Inhibitors and Beyond
TKIs block the BCR-ABL1 enzyme directly, and they transformed CML from a disease that usually required a transplant into one managed with daily tablets. Imatinib was the first; second-generation drugs such as dasatinib, nilotinib, and bosutinib work faster and are used first-line or after imatinib fails. Ponatinib and asciminib are options for resistant disease, including the T315I mutation that blocks most other TKIs.
Choosing a TKI depends on the patient’s other health conditions as much as on the leukemia. For example, some agents are avoided in people with significant heart, lung, or pancreatic problems. Common side effects include fatigue, muscle cramps, rash, fluid retention, and gastrointestinal upset.
Allogeneic stem cell transplantation is now reserved for patients in advanced phases or those whose disease resists several TKIs.
Monitoring response
Response is tracked mainly with qPCR, reported on an international scale (IS) so results are comparable between labs. In my practice, adherence is the single biggest factor I can influence; missed doses are a common reason for a rising BCR-ABL1 level.
| Milestone | BCR-ABL1 (IS) | Typical target time |
|---|---|---|
| Early molecular response | 10% or lower | 3 months |
| Complete cytogenetic response (approximate) | 1% or lower | 6–12 months |
| Major molecular response (MMR) | 0.1% or lower | 12 months |
Patients who hold a deep, stable molecular response for several years may be offered a supervised trial of stopping treatment, known as treatment-free remission, with frequent PCR checks afterwards.
Frequently Asked Questions
Is C92.1 the same as chronic myeloid leukemia?
Yes. Chronic myelogenous leukemia and chronic myeloid leukemia are two names for the same disease, and both are coded C92.1 in ICD-10. The ICD-10-CM extensions C92.10, C92.11, and C92.12 add remission status.
Is CML hereditary?
No. The Philadelphia chromosome develops in a single marrow cell during life and is not present in the eggs or sperm. Family members do not need screening because of a CML diagnosis.
Will I need to take a TKI forever?
Many people take a TKI long term, but some who achieve a sustained deep molecular response can stop under close monitoring. If the BCR-ABL1 level rises afterwards, restarting treatment usually restores control.
Can CML turn into acute leukemia?
Untreated CML eventually progresses to blast phase, which behaves like acute leukemia. With consistent TKI therapy and regular monitoring, this progression has become uncommon.
Key Takeaways
- Classic CML is coded C92.1, with C92.10, C92.11, and C92.12 recording remission status; atypical CML is C92.2.
- The cause is the acquired t(9;22) translocation producing the BCR-ABL1 fusion gene.
- Diagnosis rests on blood counts, marrow examination, and genetic confirmation.
- TKIs are the cornerstone of management, guided by regular qPCR monitoring; read more in our leukemia guide.
